Open Label Study of the Efficacy, Safety and Tolerability of Zulresso in the Treatment of Adult Women With Postpartum Psychosis
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Brexanolone (Primary)
- Indications Postnatal depression
- Focus Proof of concept; Therapeutic Use
- 26 Aug 2024 Status changed from recruiting to completed.
- 11 Apr 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 11 Apr 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.